Aprea Therapeutics, Inc.

Aprea Therapeutics reported a net loss of $(3.29) million for the first quarter of 2026, an improvement from $(3.93) million in the prior year. The company's cash and cash equivalents significantly increased to $46.5 million as of March 31, 2026, up from $14.6 million at year-end 2025, primarily driven by recent private placements. This enhanced liquidity is projected to fund the company's operating expenses and capital expenditure requirements into the first quarter of 2028.

Aprea Therapeutics reported its first quarter 2026 financial results, highlighted by the successful closing of an oversubscribed $30 million private placement. The company also provided an encouraging update on its ACESOT-1051 trial for WEE1 inhibitor APR-1051, noting two partial responses and good tolerability. This financing significantly strengthens the balance sheet, extending the cash runway into Q1 2028.

Aprea Therapeutics reported Q1 2026 financial results, highlighted by the closing of an oversubscribed $30 million private placement. This financing extends the company's cash runway into Q1 2028 and will support the ongoing development of APR-1051, which showed two partial responses with encouraging tolerability in its Phase 1 ACESOT-1051 trial. The company also provided updates on its ATRN-119 program and announced a new Chief Medical Advisor.

Aprea Therapeutics, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 16, 2026. Key proposals include the election of three Class I directors, the ratification of EisnerAmper LLP as the independent auditor, and the approval of an amendment to the Company's Certificate of Incorporation to authorize a reverse stock split of common stock. The proposed reverse stock split ratio is between one-for-three and one-for-eight, with the exact ratio and timing to be determined by the Board. Stockholders will also cast non-binding advisory votes on executive compensation and the frequency of future "say on pay" votes.

Aprea Therapeutics announced that an abstract detailing early results from its first-in-human Phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation, titled "Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)," will take place on May 30, 2026. This acceptance highlights progress in the clinical development of APR-1051, a key pipeline asset for the precision medicine oncology company.